Abstract 301P
Background
This study aimed to investigate the clinical implications of desaturation during the 6-min walk test (6MWT) for postoperative cardiopulmonary complications in non-small cell lung cancer (NSCLC) patients with moderately decreased lung function.
Methods
Between January 2010 and December 2019, 312 patients whose predicted postoperative value of forced expiratory volume in 1 second (ppoFEV1) or diffusing capacity of carbon monoxide (ppoDLco) were <60% while both were ≥ 30% and who had undergone lobectomy for NSCLC without induction treatment were included this study. Patients were classified into two groups based on the presence of oxygen desaturation (SpO2 <90%) during the 6MWT, and the prevalence and risk of cardiopulmonary complications were evaluated.
Results
Overall, 39 (12.5%) patients desaturated during the 6MWT. The prevalence of cardiopulmonary complications (48.7%, p = 0.007) and pulmonary complications (33.3%, p = 0.017) was significantly higher in patients who desaturated during the 6MWT than in those who did not. However, there was no significant difference in the incidence of postoperative cardiac complications between the two groups. In multivariable-adjusted analyses, the adjusted odds ratio for postoperative cardiopulmonary complications in patients who desaturated during the 6MWT was 2.34 (95% confidence interval = 1.16–4.75) compared to those who did not.
Conclusions
Oxygen desaturation during the 6MWT significantly increased the risk of post-lobectomy cardiopulmonary complications among lung cancer patients with moderately decreased lung function. Our study suggests that oxygen desaturation during the 6WMT could provide additional information when stratifying the postoperative surgical risks in NSCLC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
303P - Long-term oncologic outcomes for patients undergoing volatile versus intravenous anesthesia for non-small cell lung cancer surgery
Presenter: Ji Hyung Hong
Session: Poster viewing 04
306P - Multimodal management and outcomes of stage III non-small cell lung cancer: KINDLE-Egypt analysis
Presenter: Rasha Aboelhassan
Session: Poster viewing 04
307P - Differential expression profiling of transcripts in stage IIIA non-small cell lung cancer (NSCLC) of smokers and non-smokers cases of north India: A geneto-environmental study
Presenter: Archana Mishra
Session: Poster viewing 04
308P - Phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)
Presenter: Masanao Nakashima
Session: Poster viewing 04
309P - Pneumonitis and corticosteroid treatment in patients with unresectable non-small cell lung cancer receiving durvalumab consolidation after definitive chemoradiotherapy
Presenter: Saori Murata
Session: Poster viewing 04
311P - Cost-effectiveness of alectinib compared with chemotherapy in first-line treatment for anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer in Thailand
Presenter: Sermsiri Sangroongruangsri
Session: Poster viewing 04
312P - ClinMatch: A clinical trial matching platform that improves trial accessibility among NSCLC patients through comprehensive genomic and clinical profiling
Presenter: Allen Chi Shing Yu
Session: Poster viewing 04
313P - A pool analysis of MET TKI SCC244 in NSCLC patients with MET overexpression
Presenter: Yongfeng Yu
Session: Poster viewing 04